Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6398MR)

This product GTTS-WQ6398MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6398MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11103MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ13800MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ6779MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ7057MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ7542MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ10625MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ13380MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ1505MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW